ceipt o	date:	09/14/2005	6	PAG Rec'd PCT/PTO 14 SEP 2005			
FORM PTO-1390 US DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE (REV. 01-2003)				ATTORNEY'S DOCKET NUMBER 124055			
	DESI	MITTAL LETTER TO TO GNATED/ELECTED OF ERNING A FILING UN	FICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/536,459			
INTERNA PCT/JP2		L APPLICATION NO. 5005	INTERNATIONAL FILING DATE November 25, 2003	PRIORITY DATE CLAIMED November 25, 2002			
TITLE OF AGENT INGRED	FOR T		DISEASES CONTAINING 4-HYDR	ROXYPIPERIDINE DERIVATIVE AS ACTIVE			
		OR DO/FO/US ADA; Kazuyuki MATSUURA					
Applicant	t herew	ith submits to the United State	s Designated/Elected Office (DO/E	O/US) the following items and other information:			
1. 🗆] This	is a FIRST submission of item	s concerning a filing under 35 U.S.	.C. 371.			
2.	This	is a SECOND or SUBSEQUE	NT submission of items concerning	g a filing under 35 U.S.C 371.			
3.		is an express reques to begin s (5), (6), (9) and (21) indicated		(35 U.S.C. 371(f)). The submission must include			
4.] The	US has been elected (Article 3	11).				
5.	A cc	py of the International Applica	ion as filed (35 U.S.C. 371(c)(2))				
	a.	is attached hereto (required	only If not communicated by the In	itemational Bureau).			
	b.	has been communicated by	the International Bureau.				
	C.	is not required, as the application	cation was filed in the United States	s Receiving Office (RO/US).			
6.] An E	inglish language translation of	the International Application as file	(35 U.S.C. 371(c)(2))			
	a.	is attached hereto.	\ /				
	b.	has been previously submit	ted under 35 U.S.O 154(d)(4).				
	C.	☐ The International Application	n was filed in English.				
7.] Ame	indments to the claims of the Ir	nternational Application under PCT	Article 19 (35 U.S.C. 371(c)(3))			
	a.	are attached hereto (require	d only if not communicated by the	International Bureau).			
	b.	have been communicated b	y the International Bureau.				
	c.	have not been made; howe	ver, the time limit for making such	mendments has NOT expired.			
	d.	have not been made and wi	Il not be plade.				
8.] An E	inglish language translation of	the arrendments to the claims und	er PC Article 19 (35 U.S.C. 371(c)(3)).			
9.] And	ath or declaration of the invent	tor(e) (35 U.S.C. 371(c)(4)).				
10.		inglish language translation of J.S.C. 371(c)(5)).	he annexes of the International Pri	eliminary Examination Report under PCT Article 36			
Items 11	1 to 20	below concern document(s)	or information included:				
11. 🛛] An I	nformation Disclosure Stateme	nt under 37 CFR 1.97 and 1.98.				
12. 🔲] An a	ssignment document for recor	ding. A separate cover sheet in co	mpliance with 37 CFR 328 and 3.31 is included.			

☐ A preliminary amengment. 13.

☐ An Application Data Sheet under 37 CFR 1.76.

15. A substitute specification.

16. ☐ A power of attorney and/or change of address letter.

17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821

18. A second copy of the published international application under 35 U.S.C. 154(d)(4).

19. second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

20. Other items or information:

0/536,459	n, see 37 C.F.R. 1.5)	INTERNATIONAL APPLICA PCT/JP2003/15005	TION NO.	ATTORNEY'S DOCKET NUMBER 124055			
21 The following fee	es are submitted:			CALCULATIONS	PTO USE ONL		
_							
BASIC NATIONAL FEE (37 CFR 1.492(a)):		\$ 300.00	\$			
SEARCH FILE (37 CFR 1	.492(b)(1)-(3)):			\$			
	SA and favorable as t all claims presented i	o novelty, inventive step in the application entering	o, and ng the \$ 0.00				
nternational search fee ()	t provided to USPTO	no later than the time a	it which	/	ľ		
he search fee is paid			\$ 400.00				
All situations not provided	for abov		\$ 500.00	/			
XAMINATION FEE (37	CFR 1.492(0)(1)-(2)):			8			
nternational preliminary e he USPTO as IPEA or IS ndustrial applicability for national stage	examination report or SA and favorable as t all claims presented	written opinion prepared o novelty, inventive step in the application enterin	d by o, and ng the				
			/	1			
Il situations not provided urcharge of \$130.00 for	for above	doeleration later than 3	\$ 200,00	s			
arliest claimed priority da	ate (37 CFR 1.492(e)).	o monais nom ne	*			
OTAL PAGES OF PPLICATION OVER 00 (- 100)	÷ 50	= t	x 250 =	s			
round up to next integ							
CLAIMS	NUMBER FILED		RATE	\$			
OTAL CLAIMS NDEPENDENT CLAIMS	- 20	-	x 50.00 = x 200.00 =	\$			
MULTIPLE DEPENDENT			+ 360.00 =	8			
IOCTII EE DEFENDENT	ODAMIO Jul applicat	TOTAL OF ABOVE	. 000.00 -	\$			
Applicant claims sma	Il entity status. See 3	37 CFR 1.27. The fees		s			
reduced by 1/2.	,			•			
			SUBTOTAL =	\$			
rocessing fee of \$130.00 ne earliest claimed priorit) for furnishing the Er by date (37 CFR 1.49)	2(f)).		\$			
			NATIONAL FRE =	\$			
ee for recording the encl eccompanied by an appro	osed assignment (37	CFR 1.21(h)). The ass	signment must be	\$			
companied by an appic	Priorio covoi sildel (3	TOTAL F	EES ENCLOSED =	3			
		,ALII		Amount to be			
	/			refunded:	s		
				charged:	S		
. Check No	in the amount of	\$ to cover the abo	ove fees is enclosed.				
. Please charge sheet is enclo	my Deposit Account	No in the amou	int of \$ to cover	the above less. A du	plicate copy of this		
	ioner is nereby autho	rized to charge any add uplicate copy of this she	litional fees which ma	y be required, a credi	t any overpayment		
Denosit Accou	charged to a credit	card. WARNING: Infor led on this form. Provi	mation on this form reide credit card information	nay become public. Cation and authorization	redit card on PTO-2038.		
Deposit Accou	your not be melde			(A)	127/-1 (-1)		
Deposit Accounts Deposit Accounts Fees are to be information s NOTE: Where an appropriate to be filled as	/ opriate time limit ur ind granted to resto	nder 37 CFR 1.495 has re the application to p	not been met, a pet ending status.	ition to revive tar CF	137(a) or (b))		
Deposit Account Fees are to be information s IOTE: Where an appropriate to filled a sEND ALL CORRESPO	opriate time limit ur and granted to resto NDENCE TO:	nder 37 CFR 1.495 has re the application to p	not been met, a pet ending status.	Ition to revive tar CP	- (137(a) or (b))		
Deposit Accol Fees are to be information s NOTE: Where an appr must be filled a SEND ALL CORPESPO OLIFF & SERRID	opriate time limit ur and granted to resto NDENCE TO: GE, PLC	nder 37 CFR 1.495 has re the application to p	ending status.	Y	(A (137(a) br (b))		
Deposit Account Fees are to be information s IOTE: Where an appropriate to filed a service of the filed as service of the fil	opriate time limit ur and granted to resto NDENCE TO: GE, PLC	nder 37 CFR 1.495 has re the application to p	ending status. NAME: Jame	es/A. Oliff	- \		
Deposit Accol Fees are to be information s NOTE: Where an appr must be filled a SEND ALL CORPESPO OLIFF & SERRID	opriate time limit ur ind granted to resto NDENCE TO: GE, PLC er: 25944	nder 37 CFR 1.495 has re the application to p	ending status. NAME: Jame	es A. Oliff ON NUMBER: 27,0	- \		

Receipt date: 09/14/2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In rethe Application of

Yasushige AKADA et al.

Application No.: 10/536,459 Group Art Unit: 1623

Filed: Max 25, 2005 Docket No.: 124055

For: AGENT FOR TREATING RESPIRATORY DISEASES CONTAINING 4-

HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PGG-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of his application, and that the references be made of record therein and appear among the "References Ched" on any patent to issue therefrom.

- I. This Information Discloser's Statement is being filed (a) within three months of the U.S. filing date of this non-PA application, OR to before the mailing date of a first Office Action on the merits of the present application. No certification or fee is required.
- Relevance of the references is discussed in the present specification.

Respectfully submitted,

James A. Oliff Registration No. 27,075

Jesse O. Collier Registration No. 53,839

JAO:/OC/nxy

Date: September 14, 2005

OLIFF & BERRIDGE, PLC P.O. Box 19928

Alexandria, Virginia 22320

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our

TelephAdet (POEPER ANCES CONSIDERED EXCEPTION HOLD IS OR OUGH.

Receipt date: 09/14/2005

						Sheet	<u> </u>	or 1		
Form PTO-1449 (REV. 8-83)				ATTY DOCKET NO. 124055		APPLICATION NO. 10/536,459				
INFOR	RMATIO	ON DISCLOSURE STATEMENT								
(Use several sheets if necessary)				APPLICANTS Yasushige AKADA et al.						
				FILING DATE May 25, 2005			GROUP 1623			
	,	U.S.	PATENT DOC	JMENTS			,			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME		CLASS	SUB CLASS		
	,	*								
		FOREIC	N PATENT DO	OCUMENTS						
		DOCUMENT NUMBER	DATE		COUNTRY		CLASS	SUB CLASS		
	1.	WO 93/02052 A1	02/04/1993	WIPO						
	2.	WO 00/06545 A1	02/10/2000	WIPO						
	3.	WO 02/22572 A2	03/21/2002	WIPO						
	4.	OTHER DOCUMENTS (Inc				ridinas	Naw Close	of .		
		Bruno S. HUEGI et al.; "Synthesis and Pharmacological Studies of 4,4-Disubstituted Piperidines: A New Class of Compoundswith Potent Analgesic Properties"; J. Med. Chem.; 1983; Vol 26; pp. 42-50.								
		4								
		:								
EXAMINER	/Tac	Date CONSUBERED								
Examiner: In	Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									